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Bronchoscopy
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Objectives: The primary objective of this study was to evaluate the
benefit of using a new fluorescence-reflectance imaging system, Onco-
LIFE, for the detection and localization of intraepitheal neoplasia and
early invasive squamous cell carcinoma. A secondary objective was to
evaluate the potential use of quantitative image analysis with this device
for objective classification of abnormal sites.
Design: This study was a prospective, multicenter, comparative,
single arm trial. Subjects for this study were aged 45 to 75 years and
either current or past smokers of more than 20 pack-years with
airflow obstruction, forced expiratory volume in 1 second/forced
vital capacity less than 75%, suspected to have lung cancer based on
either sputum atypia, abnormal chest roentgenogram/chest com-
puted tomography, or patients with previous curatively treated lung
or head and neck cancer within 2 years.
Materials and Methods: The primary endpoint of the study was to
determine the relative sensitivity of white light bronchoscopy
(WLB) plus autofluorescence-reflectance bronchoscopy compared
with WLB alone. Bronchoscopy with Onco-LIFE was carried out in
two stages. The first stage was performed under white light and
mucosal lesions were visually classified. Mucosal lesions were
classified using the same scheme in the second stage when viewed
with Onco-LIFE in the fluorescence-reflectance mode. All regions
classified as suspicious for moderate dysplasia or worse were biop-
sied, plus at least one nonsuspicious region for control. Specimens
were evaluated by the site pathologist and then sent to a reference
pathologist, each blinded to the endoscopic findings. Positive lesions
were defined as those with moderate/severe dysplasia, carcinoma in situ
(CIS), or invasive carcinoma. A positive patient was defined as having
at least one lesion of moderate/severe dysplasia, CIS, or invasive
carcinoma. Onco-LIFE was also used to quantify the fluorescence-
reflectance response (based on the proportion of reflected red light to
green fluorescence) for each suspected lesion before biopsy.
Results: There were 115 men and 55 women with median age of 62
years. Seven hundred seventy-six biopsy specimens were included.
Seventy-six were classified as positive (moderate dysplasia or
worse) by pathology. The relative sensitivity on a per-lesion basis of
WLB  FLB versus WLB was 1.50 (95% confidence interval [CI],
1.26–1.89). The relative sensitivity on a per-patient basis was 1.33
(95% CI, 1.13–1.70). The relative sensitivity to detect intraepithelial
neoplasia (moderate/severe dysplasia or CIS) was 4.29 (95% CI, 2.00–
16.00) and 3.50 (95% CI, 1.63–12.00) on a per-lesion and per-patient
basis, respectively. For a quantified fluorescence reflectance response
value of more than or equal to 0.40, a sensitivity and specificity of 51%
and 80%, respectively, could be achieved for detection of moderate/
severe dsyplasia, CIS, and microinvasive cancer.
Conclusions: Using autofluorescence-reflectance bronchoscopy as
an adjunct to WLB with the Onco-LIFE system improves the
detection and localization of intraepitheal neoplasia and invasive
carcinoma compared with WLB alone. The use of quantitative
image analysis to minimize interobserver variation in grading of
abnormal sites should be explored further in future prospective
clinical trial.
Key Words: Autofluorescence, Bronchoscopy, Early detection,
Lung neoplasm, Screening, Intraepithelial neoplasm, Dysplasia.
(J Thorac Oncol. 2009;4: 49–54)
Lung cancer is the most common cause of cancer andcancer-deaths in the world.1,2 It accounts for 13% of new
cancer diagnoses, is the leading cause of cancer-related
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deaths in men and women, and is responsible for 29% of all
cancer deaths. Lung cancer survival is strongly associated
with the stage of disease and tumor size at the time of
diagnosis3—the 5-year relative survival rate when disease is
diagnosed at a local stage is 49%, but drops to 2% if the
cancer has spread from the primary tumor. Five-year survival
rates are significantly higher for preinvasive stage 0 lung cancers
(carcinoma in situ [CIS]) at approximately 74 to 91%.4–6 Cur-
rently, only 16% of lung cancers are diagnosed when disease is
localized and few lung cancers are diagnosed at stage 0, result-
ing in a combined 5-year survival rate of only 15%.7
White light bronchoscopy (WLB) is usually used in the
detection of lung cancer. Nevertheless, although conventional
bronchoscopy can be used to detect early lung cancer, the
detection of preinvasive lesions is difficult even for experi-
enced bronchoscopists. A study by Woolner et al.8 showed
that only 29% of CIS lesions were visible to experienced
bronchoscopists. The detection of moderate to severe dyspla-
sia is even more difficult under WLB.
Autofluorescence endoscopy (AFB) improves the sen-
sitivity for detection of preinvasive lesions in the lung.9 AFB
capitalizes on the observation that when the bronchial surface
is illuminated by blue/violet light, normal bronchial tissues
fluoresce strongly in the green, whereas premalignant and
malignant tissues have significantly lower green autofluores-
cence.10–13 AFB, when used as an adjunct to WLB, capital-
izes on this difference to enhance a bronchoscopist’s ability
to differentiate areas of intraepithelial neoplasia in the tra-
cheobronchial tree.6,9,13–28 In addition to single center studies,
two multicenter and single as well as two randomized clinical
trials have documented the usefulness of AFB as an adjunct to
WLB for detection of high-grade dysplasia and CIS.9,17,28,29
The newly developed Onco-LIFE device (Onco-LIFE
Endoscopic Light Source and Video Camera; Xillix Technol-
ogies Corp.; Richmond, BC, Canada) is a multimode bron-
choscopic imaging system for both white light and fluorescence
bronchoscopy. In white light mode, the device functions similar
to the conventional fiberoptic bronchoscopic imaging sys-
tems, illuminating the tissue with a broad spectrum, visible
light, and acquiring full color video images. In fluorescence
mode, the device uses blue light (395–445 nm) and small
amount of red light (675–720 nm) from a filtered mercury arc
lamp for illumination. The Onco-LIFE camera then captures
and combines the green autofluorescence image and red
reflectance image and displays the combined fluorescence-
reflectance images at normal video rates on a color video
monitor. Whereas the green autofluorescence image will
change with the pathology of the bronchial tissue, the red
reflectance image intensity is not significantly affected by
tissue pathology and can therefore be used as a reference
signal that corrects for differences in light intensities from
changes in angle and distance of the bronchoscope from the
bronchial surface. An area demarcated by a small target in the
center of the displayed fluorescence-reflectance image is
further processed and a value based on the ratio of red
reflectance to green fluorescence signal intensities in that area
is calculated.
Combining the red reflectance image with the green
fluorescence image has the theoretical advantage of enhanc-
ing the contrast between premalignant, malignant, and normal
tissues (when compared with the use of red fluorescence
image in earlier technology) and also of improving image
definition, because reflected light images can be captured
with less sensitive, but more spatially precise image sensors.
Using reflected red light as a reference also has the theoretical
advantage over using reflected blue/green light in that it is
absorbed less by hemoglobin and hence may be influenced
less by changes in vascularity associated with inflammation.
Red light is also more uniformly scattered within the tissue.
It is re-emitted in a more diffuse manner than blue or green
light and may serve as a better reference.
The primary objective of this study was to determine
whether using such autofluorescence-reflectance bronchos-
copy (ARB) as an adjunct to WLB with Onco-LIFE could
improve the bronchoscopist’s ability to locate areas suspi-
cious of moderate/severe dysplasia, CIS, and invasive carci-
noma as compared with WLB alone. The secondary objective
was to determine whether WLB  ARB could detect intra-
epithelial neoplasms (moderate/severe dysplasia and CIS)
better than WLB alone. In addition, as an exploratory study,
we collected data to determine whether it might be feasible to
use quantitative imaging as a computed assisted aid to min-
imize interobserver variation in classification of normal and
abnormal sites.
MATERIALS AND METHODS
This study was a multicenter, prospective, comparative,
single arm trial. Subjects first underwent WLB followed by
Onco-LIFE, and, hence, acted as their own control. Each
clinical center’s pathologist, and the reference pathologist,
was blinded to the endoscopic visual classifications of biop-
sied lesions. The institutional review board at each clinical
center approved the protocol before study initiation.
The primary efficacy endpoint was the relative sensi-
tivity of a WLB  ARB examination as compared with a
WLB examination alone for the detection of moderate/severe
dysplasia, CIS, or invasive cancer. Secondary endpoints in-
cluded an additional relative sensitivity measure for the
detection of moderate/severe dysplasia or CIS (i.e., invasive
cancer excluded from analysis). This parameter was specifi-
cally measured to ascertain the ability of WLB  ARB to
detect and localize preinvasive lesions. In addition, the false-
positive rate (i.e., 1-specificity) was determined.
To compare devices, a population with the highest
likelihood of abnormal mucosa was selected. The criteria for
enrollment in the study were aged 45 to 75 years and either
current or past smokers of more than 20 pack-years with
airflow obstruction defined as forced expiratory volume in 1
second/forced vital capacity less than 75%, suspected to have
lung cancer based on either sputum atypia, abnormal chest
roentgenogram/chest computed tomography, or patients with
previous curatively treated lung or head and neck cancer
within 2 years.
Patients were excluded if they had uncontrolled hyper-
tension, unstable angina, known or suspected pneumonia,
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acute bronchitis within the previous month, known uncon-
trollable bleeding disorders, bronchoscopy within previous 3
years with no available bronchoscopy report or more than or
equal to 1 bronchoscopy in previous 3 years with more than
four biopsies. Subjects were also excluded if they had treat-
ment with photosensitizing or retinoid chemopreventative
drugs within previous 12 months, treatment with ionizing
radiation or cytotoxic chemotherapy agents within previous 6
months, known allergy to xylocaine, fentanyl, morphine,
midazolam, diazepam, and/or codeine (if used), treatment
with anticoagulants in previous 6 days, or pregnancy. All
patients who participated in the trial gave written informed
consent. In total, 204 subjects at seven sites in Europe and
North America met the enrollment criteria. The number of
patients enrolled at each site ranged from 4 to 65.
The trial was conducted in two phases: a training phase
and a data collection phase. The training phase encompassed
18 of the 204 subjects who underwent the investigational
procedure described below. Data obtained from these sub-
jects was included in the analysis of safety, but not in the
efficacy analyses. The data collection phase encompassed the
remaining 186 subjects. Nevertheless, 16 of these patients
were excluded from efficacy analyses because of reasons,
such as unavailability of reference pathology, violation of
enrollment criteria, etc., leaving 170 subjects evaluated to
collect efficacy data.
The examination was conducted using local anesthesia
and conscious sedation with midazolam, fentanyl, or alfenta-
nyl. All bronchoscopies were videotaped and involved exam-
ination of the vocal cords, trachea, main carina, and orifices
of the subsegmental bronchi to the extent that they could be
examined without causing trauma to the bronchial wall.
Unless contraindicated, the bronchoscopist examined at least
to the third generation bronchi.
Bronchoscopy with Onco-LIFE was carried out in two
stages. The first stage was performed under white light.
During this stage, sites of interest were visually classified
(Table 1). No change in classification was allowed once the
white light examination had been completed. Under this
visual classification system, areas without any visual abnor-
mality were classified as class I. Areas with the appearance of
inflammation, trauma, anatomic abnormalities, which could
be areas of metaplasia or mild dysplasia, were classified as
class II. Areas suggestive of moderate dysplasia, severe
dysplasia, or CIS were class III. Appearance of a gross,
visible tumor was classified as class IV.
After WLB, the device was switched to ARB mode and
another examination of the airways was performed. Areas of
interest were visually classified using the same classification
scheme (Table 1). Sites classified as III or IV under ARB but
not classified under WLB were automatically defaulted to
class I under white light. Still images of all sites of interest
were recorded with a digital image capture system under both
WLB and ARB. During capture of the still image under ARB
mode, the endoscopist tried to center a small target over the
most abnormal part of the lesion. A value for the fluores-
cence-reflectance response based on the red to green light
intensity ratio in this area was computed by Onco-LIFE. This
value was recorded automatically by the digital image capture
system. The bronchoscopist was blinded to this value, be-
cause it was not displayed on the video monitor. The visual
classification results and recorded fluorescence-reflectance
response values were used for comparison with the pathology
of the biopsies after the trial had been completed.
After ARB examination, all regions classified as III or
IV under either imaging modality were biopsied, as well as at
least one class I/II region as a control. Biopsy was acquired
under ARB unless the lesion was only visible under WLB.
The clinical center’s pathologist, who was blinded to the
endoscopic findings, first evaluated the biopsy slide followed
by a reference pathologist who was blinded to the previous
results. Pathologists coded the biopsy slides based on a
9-point scheme (Table 2). In case of disagreement between
center and reference pathologist, slides were reread by the
reference pathologist, and these results were taken as final.
For analyses using the lesion as the basis of analysis,
positive lesions were defined as those with a visual classifi-
cation of III or IV under WLB and/or ARB and a correspond-
ing biopsy result of moderate/severe dysplasia, CIS, or inva-
sive carcinoma. For analyses using the patient as the unit of
analysis, a patient was defined as positive if they had at least
one lesion visually classified as class III or IV and a corre-
sponding biopsy result of moderate/severe dysplasia, CIS, or
invasive carcinoma for that lesion. For analyses measuring
detection of early intraepithelial lesions, the same definitions
of positive lesions and patients described above were used,
except positive pathology only included moderate/severe dys-
plasia or CIS.
TABLE 1. Description of Visual Classifications
Classification Description Finding
Class I Normal: not visually abnormal or suspicious Negative
Class II Abnormal: appearance of inflammation,
trauma, anatomical abnormalities,
metaplasia, or mild dysplasia
Negative
Class III Suspicious for preinvasive cancer: suggestive
of moderate dysplasia, severe dysplasia, or
carcinoma in situ
Positive
Class IV Suspicious for invasive cancer: appearance of
gross, visible tumor
Positive
TABLE 2. Pathology Coding
Pathology
Classification Code Description
Negative 1.x Normal
2.x Inflammation
3.x Hyperplasia
4.x Mild atypia
Positive 5.1–5.25 Moderate atypia
5.3–5.45 Severe atypia
6.x CIS
7.x Microinvasive
8.x Carcinoma
Unevaluable 9.x Unsatisfactory
CIS, carcinoma in situ.
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During the examination, all procedure-relevant data,
including adverse effects, was recorded. The subject was
followed-up 7 days after bronchoscopy to determine whether
any side effects from the procedure were experienced.
Statistical Methods
Statistically unbiased estimates of sensitivity and spec-
ificity were not possible to obtain because serial sections of
the entire tracheobronchial tree would need to be examined
after the bronchoscopic procedures for these to be defined.
Nevertheless, because the objective of the study was to
determine whether the addition of ARB examination to WLB
was better than WLB alone, the relative sensitivity, or the
ratio of the sensitivity of WLB  ARB as compared with
WLB alone, along with the 95% confidence interval (CI), was
calculated to evaluate the contribution of the fluorescence
examination to detect neoplastic lesions. A relative sensitivity
more than 1 would indicate a significant improvement of
WLB  ARB versus WLB alone. Two other statistically unbi-
ased estimates, the positive predictive value and negative pre-
dictive value, were also calculated to evaluate the performance.
The statistical analyses were calculated for all the data
combined (moderate dysplasia or worse) as well as subsets of
the data, such as moderate/severe dysplasia and CIS (intra-
epithelial neoplasia). The data were analyzed on a per-lesion
basis and a per patient basis. For the per-lesion analysis, each
biopsy specimen was evaluated and considered positive if the
final diagnosis was positive. For the per-patient analysis, each
patient was considered positive if he or she had at least one
positive lesion (biopsy).
RESULTS
There were 115 men and 55 women with a median age
of 62 years (range, 45–75 years). Approximately 99% of
subjects were current or former smokers with mean pack-
years (packs per day  number of years smoked) of 50.
Approximately 15% of subjects had a previous history of
lung cancer. A total of 864 biopsy specimens were acquired.
Of these, 88 were not evaluable: 84 because of unsatisfactory
biopsy specimen from insufficient epithelium for diagnosis, 4
because of lack of matching still image. The final pathologic
diagnoses for the remaining 776 biopsy specimens were as
follows: normal to mild dysplasia in 700, moderate dysplasia
in 33, severe dysplasia in 6, CIS in 2, microinvasive carci-
noma in 4, and invasive carcinoma in 31.
Table 3 summarizes efficacy results obtained in this
study. A total of 76 lesions were classified as positive (mod-
erate dysplasia or worse) by pathology. Thirty-six of these
lesions were detected during WLB examination. An addi-
tional 18 were detected by ARB, totaling 52 lesions. There-
fore, the relative sensitivity on a per-lesion basis of a WLB
ARB examination versus WLB alone was 1.50 (95% CI,
1.26–1.89). When the patient was used as the unit of analysis,
24 patients with positive pathology were identified during
WLB. An additional eight were identified with ARB totaling
32. Therefore, the relative sensitivity on a per-patient basis
was 1.33 (95% CI, 1.13–1.70).
The data was then analyzed to compare the ability to
detect intraepithelial lesions (moderate/severe dysplasia or
CIS). Of the 41 intraepithelial lesions, 4 (10%) were detected
by WLB. An additional 13 were detected by ARB totaling 17
(44%). Therefore, the relative sensitivity of WLB  ARB
versus WLB alone was 4.25 (95% CI, 2.00–16.00). The
specificity of WLB and ARB examination was 94% and 75%,
respectively. The ratio of false positive results (i.e., the ratio
of 1-specificity) of WLB  AF versus WLB alone for the
detection of moderate dysplasia or worse was 3.56. An
additional 10 individuals were identified with ARB totaling
14. Therefore, the relative sensitivity was 3.50 (95% CI,
1.63–12.00).
The fluorescence-reflectance response values computed
from the red-green light intensity ratios at 710 sites were
available for correlation. Sites where the target was not
directly over the abnormal part of the lesion were excluded
from the analysis. The pathology of the sites included in the
analysis was normal/hyperplasia (37), inflammation (3),
metaplasia (479), mild dysplasia (150), moderate dysplasia
(29), severe dysplasia (8), CIS (1), microinvasive cancer (3).
The receiver operating characteristic curve of lesions with mod-
erate dysplasia or worse versus lower grade lesions is shown in
Figure 1. The area under the curve is 0.735. Using a value of
more than or equal to 0.40 as a threshold, a sensitivity of 51%
and a specificity of 80% could be achieved.
All 204 patients enrolled were included in the analysis
of safety. On average, bronchoscopy, including WLB, ARB,
and biopsy acquisition, took 22 minutes. Adverse effects
were observed in nine patients. All adverse effects observed
were commensurate with bronchoscopy, and none were at-
tributable to the Onco-LIFE device. Serious complications
include fever and hypoxia resulting in hospitalization in four
patients. One patient experienced hypoxia requiring manual
ventilation. One individual died after the 7-day follow-up
period from pulmonary edema and underlying metastatic
small cell carcinoma.
TABLE 3. Summary of Efficacy Results: Sensitivity
Unit of
Analysis
Moderate Dysplasia or Worse Moderate/Severe Dysplasia/CIS
WLB WLB  ARB
Relative Sensitivity
(95% CI) WLB WLB  ARB
Relative Sensitivity
(95% CI)
Lesion 47% 71% 1.50 (1.26–1.89) 10% 44% 4.25 (2.00–16.0)
Patient 56% 74% 1.33 (1.13–1.70) 16% 56% 3.50 (1.63–12.0)
CIS, carcinoma in situ; WLB, white light bronchoscopy; ARB, autofluorescence-reflectance bronchoscopy; CI, confidence interval.
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DISCUSSION
This study evaluated the efficacy and safety of ARB
when used as an adjunct to WLB to detect lesions suspicious
for intraepithelial neoplasia and invasive carcinoma using a
new AFB bronchoscopy device. Similar to our previous study
using autofluorescence alone,9 these results confirm that ARB
significantly adds value to a conventional WLB by improving
the sensitivity of detection of diseased tissue, especially early
stage, intraepithelial neoplasias. The advantage of Onco-
LIFE compares to LIFE-Lung is that by using a combination
of reflectance and fluorescence, the image quality is im-
proved. The use of a filtered lamp instead of a laser decreases
the cost of the device and allows rapid switching between
white-light and fluorescence examinations. A similar princi-
ple has also been implemented in other devices.29–31
A direct comparative study between white-light bron-
choscopy using fiberoptic bronchoscopes as used in the
Onco-LIFE system versus charge-coupled device tipped
videobronchoscopes has not been performed. A recent study
showed that AFB using the LIFE-Lung system was still more
sensitive than WLB using state of the art video-bronchoscope
in the detection of high grade dysplasia and CIS (96% versus
72%, respectively).25 Studies using videobronchoscope for
both white-light and fluorescence examinations instead of
fiberoptic bronchoscopes showed similar improvements in
detection rates with AFB.30,31
The differences in tissue autofluorescence between
healthy and diseased areas visualized using LIFE technology
provide new information for the endoscopist to use when
assessing the health of the lung. This information has been
shown to enhance the physicians’ ability to detect intraepi-
thelial dysplasia or neoplasia, even above and beyond any
benefit obtained from improved image resolution obtained
with a conventional white light videoscope.27 Since its intro-
duction into the field in 1998, AFB has been used for
numerous applications, such as molecular biology studies of
lung carcinogenesis, chemoprevention trials, and monitoring
areas of field cancerization during intervention of preneopla-
sia.32–34 The improved sensitivity provided by AFB has also
been used in postinterventional surveillance, such as evalua-
tion of the recurrence of CIS in bronchial resection margins34
and postoperative surveillance of patients with non-small cell
lung cancer.19 In addition, AFB has been used to overcome
the difficulty WLB has in identifying early mucosal lesions
amenable to photodynamic therapy curative therapy.35
As observed in this study, improved sensitivity for the
detection of disease obtained through the adjunctive use of
AFB is associated with an increase in false positives, result-
ing in acquisition of more biopsies for evaluation. Neverthe-
less, the high sensitivity, lower specificity of AFB are com-
mensurate with other imaging modalities, such as computed
tomography,36 as well as occult blood testing and mammog-
raphy.37 Moreover, it has been suggested that lesions ob-
tained under AFB and denoted as false positives may be from
sites carrying molecular genetic lesions associated with ma-
lignancy despite their normal histologic appearance.38 Our
exploratory study using quantitative imaging suggested that a
good sensitivity and specificity could be achieved with com-
puted assisted aid. This approach should be incorporated into
future prospective clinical trials.
Narrow Band Imaging (NBI) uses blue light centered at
415 nm and green light centered at 540 nm corresponding to
the maximal hemoglobin absorption peaks. The blue light
highlights the superficial capillaries, whereas the green light
can penetrate deeper and highlight the larger blood vessels in
the submucosa. Preliminary studies suggest that NBI can
improve detection of dysplasia and CIS compared with
WLB.39 A direct comparison between NBI and autofluores-
cence bronchoscopy has not been done. Some NBI studies
use NBI to evaluate localized sites of interest that are detected
with AFB.40
The next step in the assessment of the clinical utility of
LIFE technology is to evaluate the link between improved
detection of disease achievable with this technology and
improved long-term patient outcome. Toward this goal, an
international Autofluorescence Bronchoscopy Registry for
Intraepithelial Neoplasia coordinated by the Rosewell Park
Cancer Institute Stacey Scott Lung Cancer Registry is under-
way to establish a large database to determine the long-term
outcome of patients undergoing AFB.
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